Damora Therapeutics (DMRA) Total Liabilities (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Total Liabilities came in at $23.8 million in Q1 2026, up 1339.55% YoY from $1.7 million in Q1 2025, and up 18.33% on a QoQ basis from $20.1 million in Q4 2025.
Damora Therapeutics (DMRA) Total Liabilities (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Total Liabilities data on file, last reported at $23.8 million in Q1 2026.
- Quarterly Total Liabilities rose 1339.55% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 1339.55% YoY) and the FY2025 annual result came in at $20.1 million, up 1448.58% from the prior year.
- Total Liabilities improved to $23.8 million in Q1 2026, from $20.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $23.8 million in Q1 2026 to a low of $1.3 million in Q4 2024.
- A 5-year average of $8.6 million and a median of $7.6 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities sank 80.73% — and 2025, when it surged 1448.58%.
- Tracing DMRA's Total Liabilities over 5 years: stood at $11.4 million in 2022, then plunged by 48.44% to $5.9 million in 2023, then slumped by 77.93% to $1.3 million in 2024, then surged by 1448.58% to $20.1 million in 2025, then increased by 18.33% to $23.8 million in 2026.
- The last three Total Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 27.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.58 Mn |
| Mar 31, 2026 | 23.84 Mn |
| Dec 31, 2025 | 20.15 Mn |
| Sep 30, 2025 | 2.73 Mn |
| Jun 30, 2025 | 2.74 Mn |
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 5.90 Mn |
| Sep 30, 2023 | 12.67 Mn |
| Jun 30, 2023 | 15.10 Mn |
| Mar 31, 2023 | 14.30 Mn |
| Dec 31, 2022 | 11.44 Mn |
| Sep 30, 2022 | 9.30 Mn |
| Jun 30, 2022 | 7.79 Mn |
| Mar 31, 2022 | 7.62 Mn |
| Dec 31, 2021 | 4.99 Mn |
| Sep 30, 2021 | 6.25 Mn |